6+ hour, 50+ min ago  (707+ words) As BIO 2026 approaches, industry experts weigh in on the conversations likely to dominate the floor " from AI and funding pressures to manufacturing readiness, regulatory uncertainty, and the challenge of turning innovation into real-world impact For Biopharma Vital Signs, we asked…...

2+ day, 12+ hour ago  (871+ words) Why no single player can solve the scalability challenge alone The operational constraints facing drug manufacturers today are rampant. They show up as long development timelines, fragile and complex manufacturing processes, limited capacity, talent gaps, fragmented data, and regulatory uncertainty....

3+ day, 16+ hour ago  (478+ words) The study points to a possible off-the-shelf cell therapy for solid tumors Tissue-resident natural killer cells generated from donor blood slowed the growth of solid tumors in mice and could form the basis of an off-the-shelf cell therapy, according to…...

3+ day, 17+ hour ago  (338+ words) Researchers found gene therapy produced the highest modeled health benefit, but haploidentical stem cell transplantation offered better value at current prices Non-myeloablative haploidentical allogeneic stem cell transplantation was the most cost-effective long-term treatment option for adults with sickle cell disease…...

4+ day, 13+ hour ago  (926+ words) Why patient voices must shape rare disease innovation But momentum alone isn't enough. Progress matters only when it reaches the right person at the right time, and that takes collaboration across biotech, healthcare systems, regulators, and patient communities. It also…...

4+ day, 15+ hour ago  (407+ words) The clinical-stage cancer biotech raised $670 million in an upsized Nasdaq debut, with a further $75 million expected from a concurrent Regeneron private placement Parabilis Medicines has raised $670 million in an IPO, setting a new benchmark for biotech listings on Nasdaq and…...

1+ week, 16+ hour ago  (737+ words) John Yoshi Shyu on why mesenchymal stem cell programs stall " and how early manufacturing decisions can determine clinical and commercial success In mesenchymal stem cell (MSC) therapy, promising early data does not guarantee long-term success. Many programs falter when the…...

1+ week, 3+ day ago  (982+ words) Akeso's PD-1/VEGF bispecific beats PD-1 plus chemo in lung cancer, Amgen wins EC approval for its DLL3-targeted T-cell engager, and Aragen scales Renaissance's Fast Track anti-GD2 antibody Ivonescimab beats PD-1 plus chemo in first-line squamous NSCLC Akeso's ivonescimab, a…...

1+ week, 4+ day ago  (1137+ words) Antoinette Gawin discusses leadership, innovation in blood and cell therapy, and the global systems shaping access to advanced medicine As president and CEO of Terumo Blood and Cell Technologies, Antoinette Gawin leads a company involved in some of the most…...

1+ week, 4+ day ago  (1113+ words) Legend and Kelonia reveal 100 percent response rates in phase 1 trials, dual CAR T opens doors for kidney transplant patients, and i PDSC therapy beefs up failing hearts Promising phase 1 results for Legend's in vivo CAR T" Legend Biotech's in vivo…...